January 17, 2023 11:24 AM EST

MarketingRx roundup: Eli Lilly debuts unbranded ‘memory’ issues TV ad; Big Pharmas amp social media spending

Beth Snyder Bulik

Senior Editor

As Eli Lilly readies for the FDA review of Alzheimer’s disease candidate donanemab next month, it’s rolling out an unbranded, 15-second TV commercial about memory …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MarketingRx roundup: Eli Lilly debuts unbranded ‘memory’ issues TV ad; Big Pharmas amp social media spending

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mar­ket­ingRx roundup: Eli Lil­ly de­buts un­brand­ed ‘mem­o­ry’ is­sues TV ad; Big Phar­mas amp so­cial me­dia spend­ing

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

MarketingRx roundup: Eli Lilly debuts unbranded ‘memory’ issues TV ad; Big Pharmas amp social media spending